Literature DB >> 2056330

Subcutaneous and sublingual levodopa methyl ester in Parkinson's disease.

B Kleedorfer, A J Lees, G M Stern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2056330      PMCID： PMC488502          DOI： 10.1136/jnnp.54.4.373

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

1.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

2.  Subcutaneous apomorphine in Parkinson's disease.

Authors:  W Poewe; B Kleedorfer; F Gerstenbrand; W Oertel
Journal:  Lancet       Date:  1988-04-23       Impact factor: 79.321

3.  L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.

Authors:  D R Cooper; C Marrel; B Testa; H van de Waterbeemd; N Quinn; P Jenner; C D Marsden
Journal:  Clin Neuropharmacol       Date:  1984       Impact factor: 1.592
  3 in total
  4 in total

Review 1.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

2.  Perioperative sublingual levodopa in Parkisnon's Disease: A useful alternative!

Authors:  Pritee H Bhirud; Jalpa Arvind Kate
Journal:  Indian J Anaesth       Date:  2017-05

Review 3.  Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier?

Authors:  Stuart H Isaacson; Fernando L Pagan; Mark F Lew; Rajesh Pahwa
Journal:  Clin Park Relat Disord       Date:  2022-08-12

Review 4.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.